Epigenetic risk score improves prostate cancer risk assessment
Abstract
Early detection of aggressive prostate cancer (PCa) remains crucial for effective treatment of patients. However, PCa screening remains controversial due to a high rate of overdiagnosis and overtreatment. To better reconcile both objectives, more effective methods for assessing disease severity at the time of diagnosis are needed.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 01, 2017
- Source ID
- 10.1002/pros.23385
Entities
People
- Gary P. Kearney
- George W. Adams
- Jack Groskopf
- James E. Bryant
- Leander Van Neste
- Mark S. Deguenther
- Michael C. Kearney
- Peter N. Kolettis
- Sandra M. Gaston
- William E. Grizzle
- Wim Van Criekinge
Organizations
- Ghent University
- Harvard Medical School
- Maastricht University
- National Cancer Institute
- Tufts University
- United States Department of Defense
- University of Alabama at Birmingham